Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory

D Cragun, C Radford, J S Dolinsky, M Caldwell, E Chao, T Pal, D Cragun, C Radford, J S Dolinsky, M Caldwell, E Chao, T Pal

Abstract

Next-generation sequencing enables testing for multiple genes simultaneously ('panel-based testing') as opposed to sequential testing for one inherited condition at a time ('syndrome-based testing'). This study presents results from patients who underwent hereditary colorectal cancer (CRC) panel-based testing ('ColoNext(™) '). De-identified data from a clinical testing laboratory were used to calculate (1) frequencies for patient demographic, clinical, and family history variables and (2) rates of pathogenic mutations and variants of uncertain significance (VUS). The proportion of individuals with a pathogenic mutation who met national syndrome-based testing criteria was also determined. Of 586 patients, a pathogenic mutation was identified in 10.4%, while 20.1% had at least one VUS. After removing eight patients with CHEK2 mutations and 11 MUTYH heterozygotes, the percentage of patients with 'actionable' mutations that would clearly alter cancer screening recommendations per national guidelines decreased to 7.2%. Of 42 patients with an 'actionable' result, 30 (71%) clearly met established syndrome-based testing guidelines. This descriptive study is among the first to report on a large clinical series of patients undergoing panel-based testing for inherited CRC. Results are discussed in the context of benefits and concerns that have been raised about panel-based testing implementation.

Keywords: ColoNext; clinical genetics; hereditary cancer syndromes; multiplex genetic testing; next generation sequencing; variants of unknown significance.

© 2014 The Authors. Clinical Genetics published by John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Figures

Fig 1
Fig 1
Gene alterations identified through ColoNext™ testing and number of patients with actionable mutations who met NCCN testing, screening, or diagnostic criteria.

References

    1. American Cancer Society. Atlanta, GA: American Cancer Society; Colorectal Cancer Facts & Figures 2011–2013 [Online]. Retrieved January 2, 2014, from .
    1. Burt RW. Colon cancer screening. Gastroenterology. 2000;119:837–853.
    1. Järvinen HJ, Aarnio M, Mustonen H. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.
    1. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793–4797.
    1. Pritchard CC, Smith C, Salipante SJ. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012;14:357–366.
    1. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–1270.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening Version 2.2013 [Online]. NCCN. Retrieved January 2, 2014, from .
    1. Bombard Y, Bach PB, Offit K. Translating genomics in cancer care. J Natl Compr Canc Netw. 2013;11:1343–1353.
    1. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.
    1. ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn. 2008;10:484–492.
    1. Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009;85:142–154.
    1. Walsh T, Lee MK, Casadei S. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010;107:12629–12633.
    1. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature review. Hered Cancer Clin Pract. 2013;11:9.
    1. Hayward BE, De Vos M, Valleley EM. Extensive gene conversion at the PMS2 DNA mismatch repair locus. Hum Mutat. 2007;28:424–430.
    1. Plon SE, Eccles DM, Easton D. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–1291.
    1. Richards CS, Bale S, Bellissimo DB. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10:294–300.
    1. Lucci-Cordisco E, Risio M, Venesio T, Genuardi M. The growing complexity of the intestinal polyposis syndromes. Am J Med Genet A. 2013;161A:2777–2787.
    1. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med; [Epub ahead of print]; 2013. Retrieved January 2, 2014, from .
    1. Cybulski C, Gorski B, Huzarski T. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75:1131–1135.
    1. Nieuwenhuis MH, Vogt S, Jones N. Evidence for accelerated colorectal adenoma – carcinoma progression in MUTYH-associated polyposis? Gut. 2012;61:734–738.
    1. Webb EL, Rudd MF, Houlston RS. Colorectal cancer risk in monoallelic carriers of MYH variants. Am J Hum Genet. 2006;79:768–771. author reply 771–762.
    1. Farrington SM, Tenesa A, Barnetson R. Colorectal cancer risk in monoallelic carriers of MYH variants – reply. Am J Hum Genet. 2006;79:771–772.
    1. Eggington J, Burbidge L, Roa B, et al. Presented at American College of Medical Genetics Annual Meeting, 2012; Current variant of uncertain significance rates in BRCA1/2 and Lynch syndrome testing. Online]. Retrieved January 2, 2014, from .
    1. Grace K, Schaller J, Eggington J, et al. CGA-ICC Annual Meeting; 2013. Mutation breakdown and variant rates in Lynch syndrome. Online]. Retrieved January 2, 2014, from .
    1. Plon SE, Cooper HP, Parks B. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 13:148–154.
    1. Pal T, Cragun D, Lewis C. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers. 2013;17:367–375.
    1. Wideroff L, Vadaparampil ST, Greene MH. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet. 2005;42:749–755.
    1. Fitzgerald RC1, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–444.
    1. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe